Drug-induced autoimmune hepatitis: A minireview
- PMID: 35979160
- PMCID: PMC9260871
- DOI: 10.3748/wjg.v28.i24.2654
Drug-induced autoimmune hepatitis: A minireview
Abstract
Drug-induced autoimmune hepatitis (DIAIH) is a specific phenotype of drug-induced liver injury that may lead to the devastating outcome of acute liver failure requiring liver transplantation. Drugs implicated in DIAIH include antimicrobials such as nitrofurantoin and minocycline, non-steroidal anti-inflammatory drugs, statins as well as anti-tumor necrosis agents. The clinical features of drug-induced liver injury are indistinguishable from idiopathic autoimmune hepatitis (AIH) as both may have positive AIH-related autoantibodies, elevated immunoglobulin G, as well as similar histopathological findings. In patients who show no clinical improvement, or there is progressive liver injury despite cessation of the suspected drug, a liver biopsy should be considered, whereby the presence of advance fibrosis on histology favors the diagnosis of idiopathic AIH. Empirical treatment with corticosteroids may be required in patients with non-resolving liver injury. A typical clinical scenario supportive of DIAIH includes a history of drug exposure with spontaneous resolution of liver injury after drug withdrawal and the absence of relapse after rapid steroid taper. In this article we report two cases of DIAIH secondary to Sorafenib and Atorvastatin along with a review of currently available literature. Early identification and treatment often lead to a favorable outcome in DIAIH.
Keywords: Autoimmune hepatitis; Drug-induced autoimmune hepatitis; Drug-induced liver injury; Review.
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: All authors have no relevant conflict of interest to report.
Figures



Similar articles
-
Drug-induced autoimmune hepatitis: clinical characteristics and prognosis.Hepatology. 2010 Jun;51(6):2040-8. doi: 10.1002/hep.23588. Hepatology. 2010. PMID: 20512992
-
A case of synthetic oestrogen-induced autoimmune hepatitis with microvesicular steatosis.J Clin Pharm Ther. 2014 Oct;39(5):573-6. doi: 10.1111/jcpt.12191. Epub 2014 Jul 3. J Clin Pharm Ther. 2014. PMID: 24989642
-
Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report.J Hepatol. 2023 Sep;79(3):853-866. doi: 10.1016/j.jhep.2023.04.033. Epub 2023 May 8. J Hepatol. 2023. PMID: 37164270 Free PMC article. Review.
-
Relapse and Need for Extended Immunosuppression: Novel Features of Drug-Induced Autoimmune Hepatitis.Digestion. 2023;104(3):243-248. doi: 10.1159/000528329. Epub 2023 Jan 5. Digestion. 2023. PMID: 36603570
-
Drug-induced autoimmune-like hepatitis.Dig Dis Sci. 2011 Apr;56(4):958-76. doi: 10.1007/s10620-011-1611-4. Epub 2011 Feb 16. Dig Dis Sci. 2011. PMID: 21327704 Review.
Cited by
-
Double Trouble: Drug-Induced Autoimmune Hepatitis (AIH)-Primary Biliary Cholangitis (PBC) Overlap Syndrome Triggered by Hydralazine.Cureus. 2025 May 19;17(5):e84405. doi: 10.7759/cureus.84405. eCollection 2025 May. Cureus. 2025. PMID: 40535405 Free PMC article.
-
The progress of autoimmune hepatitis research and future challenges.Open Med (Wars). 2023 Oct 30;18(1):20230823. doi: 10.1515/med-2023-0823. eCollection 2023. Open Med (Wars). 2023. PMID: 38025543 Free PMC article. Review.
-
Treatment of Drug-Induced Liver Injury.Biomedicines. 2022 Dec 21;11(1):15. doi: 10.3390/biomedicines11010015. Biomedicines. 2022. PMID: 36672522 Free PMC article. Review.
-
Clinicopathological characteristics of autoimmune‑like hepatitis after drug‑induced liver injury.Biomed Rep. 2025 Feb 25;22(4):75. doi: 10.3892/br.2025.1953. eCollection 2025 Apr. Biomed Rep. 2025. PMID: 40083601 Free PMC article.
-
Autoimmune hepatitis: clinicopathological characteristics and histopathological diagnosis in the light of current views.Clin Exp Hepatol. 2025 Mar;11(1):14-24. doi: 10.5114/ceh.2025.148233. Epub 2025 Mar 31. Clin Exp Hepatol. 2025. PMID: 40303581 Free PMC article. Review.
References
-
- Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–1425, 1425.e1. - PubMed
-
- Shen T, Liu Y, Shang J, Xie Q, Li J, Yan M, Xu J, Niu J, Liu J, Watkins PB, Aithal GP, Andrade RJ, Dou X, Yao L, Lv F, Wang Q, Li Y, Zhou X, Zhang Y, Zong P, Wan B, Zou Z, Yang D, Nie Y, Li D, Wang Y, Han X, Zhuang H, Mao Y, Chen C. Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. Gastroenterology. 2019;156:2230–2241.e11. - PubMed
-
- Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM U. S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947–954. - PubMed
-
- Wei G, Bergquist A, Broomé U, Lindgren S, Wallerstedt S, Almer S, Sangfelt P, Danielsson A, Sandberg-Gertzén H, Lööf L, Prytz H, Björnsson E. Acute liver failure in Sweden: etiology and outcome. J Intern Med. 2007;262:393–401. - PubMed
-
- Björnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol. 2005;40:1095–1101. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical